TG Therapeutics (TGTX) Company Overview

TG Therapeutics shared updates at the JP Morgan Healthcare conference this month, with CEO Weiss discussing both commercial progress and pipeline developments. Briumvi showed impressive sales of $103.6 million in Q4 2024, indicating its growth potential even with new competition from Roche's Ocrevus Zunovo. Additionally, the company announced that subcutaneous Briumvi will begin phase 3 trials in mid-2025, and they are also working on new trials to enhance the convenience of IV Briumvi and expand its use in myasthenia gravis.

TG Therapeutics surpassed its 2024 revenue expectations by 24%, showing impressive growth and gaining market share with its Multiple Sclerosis drug, Briumvi. Although the revenue forecast for 2025 is $540 million, which suggests slower growth, management believes there is a chance for much higher earnings, potentially hitting $605 million. The CEO's remarks and the performance in the fourth quarter point to a steady increase of 15-20% in new patients, supported by future advertising and greater recognition among influential experts.

TG Therapeutics (TGTX) saw significant movement in the last trading session with trading volume above average. However, the recent changes in earnings estimates may not support the stock's upward momentum in the short term.

TG Therapeutics is currently selling an IV infusion of Briumvi and is also working on a subcutaneous version to better compete with other multiple sclerosis treatments. The company plans to share initial results for the subcutaneous Briumvi in early 2025, and they are optimistic about its potential. Although they have authorized a $100 million share buyback, they only repurchased $2.1 million in the third quarter of 2024, but more buybacks could help support the stock price.

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) has announced that it has been named the top company on the Deloitte Technology Fast 500™. This ranking highlights the 500 fastest-growing companies in sectors like technology, media, telecommunications, life sciences, fintech, and energy tech in North America, and it is now in its 30th year.

TG Therapeutics, Inc. had a small improvement in their Q3 results and increased their full-year sales forecast for Briumvi by $7.5 million at the midpoint. Although the results were a bit disappointing, they met the company's expectations for a weaker Q3. Now, we look forward to key updates in early 2025, including preliminary Q4 sales for Briumvi, guidance for 2025, and initial trial results for subcutaneous Briumvi.

TG Therapeutics, Inc. (NASDAQ:TGTX) will hold its Q3 2024 earnings conference call on November 4, 2024, at 8:30 AM ET. The call will feature company representatives including Jenna Bosco, Michael Weiss, Adam Waldman, and Sean Power. Participants from various financial institutions will also join the call, including Ed White from H.C. Wainwright and Michael DiFiore from Evercore ISI.

TG Therapeutics (TGTX) reported quarterly earnings of $0.02 per share, which is lower than the Zacks Consensus Estimate of $0.04 per share. This is a decrease compared to earnings of $0.73 per share from the same period last year.

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) has announced that they will hold a conference call on Monday, November 4, 2024, at 8:30 AM ET. The call will cover the results for the third quarter of 2024 and share the company's outlook for the rest of the year. Michael S.